AZD0486 + Rituximab for Follicular Lymphoma
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What evidence supports the effectiveness of the drug combination AZD0486 and Rituximab for treating follicular lymphoma?
Rituximab, when combined with chemotherapy, has been shown to improve response rates and progression-free survival in patients with follicular lymphoma, and it is considered a standard treatment. Although specific data on AZD0486 is not provided, the combination of rituximab with other biological agents has been effective in enhancing treatment outcomes.12345
What safety data exists for AZD0486 + Rituximab treatment?
Rituximab, used in various conditions, generally has tolerable side effects like fevers and chills during the first infusion, but can also cause rare cases of severe thrombocytopenia (low platelet count). It is considered safe for long-term use in some lymphomas, though some patients may experience reversible low blood cell counts.678910
What makes the drug AZD0486 + Rituximab unique for treating follicular lymphoma?
The combination of AZD0486, a novel bispecific antibody targeting CD19 and CD3, with Rituximab, a well-established monoclonal antibody targeting CD20, offers a unique approach by engaging both T-cells and B-cells to enhance the immune response against follicular lymphoma, potentially improving treatment outcomes compared to standard therapies that typically target only one type of cell.67111213
What is the purpose of this trial?
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the AZD0486 plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.
Research Team
Chan Cheah
Principal Investigator
Sir Charles Gairdner Hospital (SCGH)
Eligibility Criteria
This trial is for patients with untreated Follicular Lymphoma. Participants must meet certain health criteria to join, but specific inclusion and exclusion details are not provided here.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Safety Run-in
This part will compare dose levels of AZD0486 in combination with rituximab to establish the RP3D
Phase III Treatment
Participants receive AZD0486 plus rituximab or Investigator's choice of standard chemoimmunotherapy regimen
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- AZD0486
- Rituximab
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from รcole nationale vรฉtรฉrinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from รcole nationale vรฉtรฉrinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology